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Background: Oral propranolol reduces retinopathy of prematurity (ROP) progression,
although not safely. Propranolol 0.1% eye micro-drops administered to newborns with
stage 2 ROP are well-tolerated, but not sufficiently effective.
Methods: A multi-center open-label trial was conducted to assess the safety
and efficacy of propranolol 0.2% eye micro-drops in newborns with stage 1
ROP. The progression of the disease was evaluated with serial ophthalmologic
examinations. Hemodynamic, respiratory, biochemical parameters, and propranolol
plasma levels weremonitored. Demographic and perinatal characteristics, co-morbidities
and co-intervention incidences, together with ROP progression, were compared
with a historical control group in the same centers participating in the trial.
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Results: Ninety-eight newborns were enrolled and compared with the historical control
group. Populations were not perfectly homogeneous (as demonstrated by the differences
in the Apgar score and the different incidence rate in surfactant administration and
oxygen exposure). The progression to ROP stage 2 or 3 plus was significantly lower
than the incidence expected on the basis of historical data (Risk Ratio 0.521, 95% CI
0.297– 0.916). No adverse effects related to propranolol were observed and the mean
propranolol plasma level was significantly lower than the safety cut-off of 20 ng/mL.
Unexpectedly, three newborns treated with oral propranolol before the appearance of
ROP, showed a ROP that was unresponsive to propranolol eye micro-drops and required
laser photocoagulation treatment.
Conclusion: Propranolol 0.2% eye micro-drops were well-tolerated and appeared
to reduce the ROP progression expected on the basis of a comparison with a
historical control group. Propranolol administered too early appears to favor a more
aggressive ROP, suggesting that a β-adrenoreceptor blockade is only useful during the
proliferative phase. Further randomized placebo-controlled trials are required to confirm
the current results.
Clinical Trial Registration
The trial was registered at ClinicalTrials.gov with Identifier NCT02504944 and with
EudraCT Number 2014-005472-29.
Keywords: propranolol, beta blocker, proliferative retinopathy, angiogenesis, preterm newborn
INTRODUCTION
Despite remarkable progress in many areas of neonatal medicine,
retinopathy of prematurity (ROP) remains a very common and
disabling complication of premature birth (1). Even though ROP
is currently considered a multi-factorial disease that involves
both oxygen-dependent and oxygen-independent factors such as
nutritional intakes (2), phenomena such as low gestational age
(GA), low birthweight, and supplemental oxygen therapy are the
main factors associated with it (3). Currently, the possibility to
prevent or slow down the progression of ROP is predominantly
dependent on a controlled and careful use of oxygen, but
the possibility of pharmacological interventions arouses great
interest (4).
ROP is a typical oxygen-dependent biphasic disease, where
what happens in the first phase, following oxygen exposure,
apparently mirrors what happens during the second phase,
when the retina becomes hypoxic (3). In the hypoxic uterine
environment, retinal vascularization begins from the 16th week
of gestation, and is completed at∼40 weeks of GA. Very preterm
newborns are born with peripheral retinae that are still avascular.
The exposure to a hyperoxic environment induces the down-
regulation of retinal pro-angiogenic factors, such as VEGF, which
Abbreviations: ROP, Retinopathy of Prematurity; GA, Gestational Age; OIR,
Oxygen-induced Retinopathy; β-AR, β-adrenoreceptor; HIF, Hypoxia-Induced
Factor; VEGF, Vascular Endothelial Growth Factor; IGF-1, Insulin Growth
Factor-1; NICU, Neonatal Intensive Care Units; AP-ROP, Aggressive Posterior
ROP; ETROP, Early Treatment for Retinopathy of Prematurity; CV, Coefficient
of Variation.
contributes to growth arrest, or even regression, of the normal
retinal vasculature. This is the first phase of ROP, the ischemic
phase, where vascular obliteration favors the transition to the
hypoxic phase. In fact, as the infant matures, the avascular
retina becomes increasingly hypoxic due to the discrepancy
between the increased metabolic demands of the maturing retina
and the rudimentary vascularization. This hypoxia induces a
localized up-regulation of proangiogenic factors, leading to the
second phase of ROP, the proliferative phase, characterized by
vaso-proliferation and retinal neovascularization. The degree
of vascular obliteration during the ischemic phase affects the
severity of retinal hypoxia, which subsequently regulates the
production of retinal VEGF in the proliferative phase (3, 5).
Recently, we have demonstrated in the murine model of
oxygen-induced retinopathy (OIR), the model usually adopted
to experimentally reproduce ROP (6), that the β-adrenergic
system plays a central role in the promotion of retinal
neovascularization. In fact, the retinal ischemia induced by
oxygen exposure promotes the release of norepinephrine, which
reacts with β2 and β3- adrenoreceptors (β-AR) inducing
the up-regulation of hypoxia-induced factor (HIF), vascular
endothelial growth factor (VEGF) and insulin growth factor
(IGF-1). Systemic propranolol, administered in mice during the
proliferative phase of OIR, reduces its progression thanks to
the down-regulation of such proangiogenic factors (7–9). Pilot
clinical trials have verified that oral propranolol administered to
newborns with ROP slows down its progression, reducing the
need for laser photocoagulation or anti-VEGF treatment (10–
13). However, this treatment aroused serious safety concerns
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because unstable preterm newborns receiving 1–2 mg/kg/day,
whose mean propranolol plasma concentrations were between 20
and 60 ng/mL, showed life-threatening adverse events. A series
of apneas, bradycardias, and hypotensions were observed in
newborns simultaneously with the development of an infection,
or during the induction of general anesthesia, or after respiratory
failure due to massive atelectasia or bronchospasm (10). Some of
these infants were refractory to adrenaline (probably due to the
β-ARs blockade), and recovered after receiving terlipressin (10).
This experience led to the exploration of topical administration
of propranolol as a possible safer approach: the objective was
to obtain an efficacy similar to what we had observed with
oral propranolol, but with plasma concentrations lower than
20 ng/mL, which is considered a sort of safe cut-off value.
This strategy was evaluated initially in animal models, and
then in newborns. In mice with OIR, propranolol eye-drops
confirmed its efficacy in counteracting retinal neovascularization
(14). In rabbits, the administration of propranolol 0.1% eye-
drops dramatically increased the retina/plasma ratio compared
with oral administration, suggesting that it was possible to
conciliate ocular efficacy with low plasma levels (15). The first
study, performed in newborns with stage 2 ROP, showed that
propranolol 0.1% eye micro-drops were well-tolerated, but not
sufficiently effective in reducing ROP progression (16). However,
the low plasma propranolol levels and the lack of adverse effects
encouraged the administration of a higher concentration (0.2%)
to newborns at an earlier stage of the disease (ROP stage 1) (17).
METHODS
Preliminary Analysis
To plan the present multi-center, open-label, single arm, phase
IIB trial, a preliminary analysis was performed to evaluate the
historical natural evolution of ROP in the neonatal intensive care
units (NICUs) involved in the trial from 2011 to 2015. The study
protocol has previously been published (17). Demographic and
perinatal characteristics of the historical cohort belonging to the
six NICUs originally participating in the trial and the percentage
of progression from stage 1 ROP at first diagnosis have also been
published (17). However, a seventh Center was added to the
study and the retrospective analysis was updated. Results of this
analysis are reported in Results section.
Definitions
In order to establish the location and severity of ROP, standard
international ROP classification was adopted (18).
Patients
From August 2015 to April 2018, preterm newborns with
GA ≤ 32 weeks and birthweight ≤ 1500 g, diagnosed with
stage 1 ROP in zone II or III, who were admitted to
the NICUs taking part in the study (University Hospital of
Florence, Milan, Monza, Siena, Varese, Brescia, and Padua)
were enrolled in this trial. Newborns with heart failure, severe
and persistent hypotension, persistent bradycardia (heart rate
<90 beats per minute), second or third-degree atrioventricular
blocks, congenital cardiovascular anomalies (except for persistent
ductus arteriosus, patent foramen ovale, and small ventricular
septal defects), renal failure, current cerebral hemorrhage, and
other diseases that contraindicate the use of β-AR blockers on
enrolment were excluded from the study. Moreover, newborns
with ROP at a more advanced stage than stage 1 at first diagnosis
and with aggressive posterior ROP (AP-ROP) were also excluded.
Intervention
Treatment with ocular propranolol 0.2 % solution was started
immediately after stage 1 ROP was diagnosed. The eye solution
was prepared sterilely by diluting propranolol hydrochloride
powder (ACEF, Fiorenzuola d’Arda, Piacenza, Italy), in sterile
water for injection at a concentration of 2%. Then, the
propranolol 0.2% solution was obtained in a horizontal laminar
flow hood, adding 9ml of saline solution to 1ml of propranolol
2% preparation (15, 17). Newborns received three micro-drops
of 6 µL (12 µg propranolol per micro-drop) in each eye, applied
with a micropipette, every 6 h. The nurses and the parents
of infants nearing discharge were instructed on how to use
the micropipette to also administer the micro-drops at home.
After each administration, the nasolacrimal duct was carefully
compressed for 30 s to decrease the drug absorption through the
conjunctival and nasal vessels. Treatment was continued until
retinal vascularization was complete, but for no longer than
90 days.
While infants were receiving supplemental oxygen, the
target range of oxygen saturation was maintained between 88
and 93%. The ophthalmologic approach was in accordance
with the guidelines adopted by the Early Treatment for
Retinopathy of Prematurity (ETROP) Cooperative Group and
international guidelines (19–21). Therefore, newborns with ROP
who progressed to stage 2 plus or 3 plus were treated with
laser photocoagulation or intravitreal anti-VEGF administration
(19). The ophthalmologists chose the treatment they considered
most appropriate.
Safety
Hemodynamic parameters, diuresis and respiratory parameters
were continuously monitored during the first 3 weeks of
treatment. Bradycardia was defined as a single heart-rate drop
below 100 bpm; apnea was defined as a pause in breathing
for more than 20s or less when associated with desaturation,
bradycardia, pallor, or reduced tone. Hypotension was defined
as mean arterial blood pressure less than the 10th centile for
gestation/birth weight and postnatal age (16). A complete blood
count, serum electrolytes levels, and renal and liver function
tests were performed before starting treatment (T0) and once a
week for the first 3 weeks of treatment (T7, T14, and T21). An
electrocardiogram and echocardiogram were performed before
starting treatment and once a week for the next 3 weeks. Any
drugs that were concomitantly administered were recorded.
Plasma Propranolol Evaluation
The plasma propranolol level was measured in dried blood spots
with the liquid-chromatography tandem-mass spectrometry
method (22) at the steady state (10th day of treatment), before
administering therapy (T0), after 2 (T2), 4 (T4), and 6 h (T6) (23).
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FIGURE 1 | The Simon two-stage optimal design algorithm of the study.
The coefficient of variation (CV), a measure of relative variability,
was calculated as the ratio of the standard deviation to the mean
propranolol values, for each point (from T0 to T6).
Efficacy
The primary outcome was the rate of progression of the
disease to ROP stage 2 or 3 plus. Complete ophthalmologic
evaluations were performed in accordance with international
guidelines (21). The ophthalmologic exam verified the absence
of local adverse events due to treatment with propranolol
eye micro-drops, and also monitored the ROP progression
using indirect ophthalmoscopy. The RetCam Imaging System
was systematically used by ophthalmologists to evaluate
ROP evolution.
Stop Criteria and Dose Changes
A strategy to follow in the event of any severe adverse events
attributable to topical propranolol, or in the case of mean
propranolol plasma concentrations being higher than 20 ng/mL,
was planned (17). Considering the high risk of adverse events
after propranolol administration in unstable newborns, in the
case of severe adverse events, ascribable to propranolol, the
treatment was to be promptly interrupted and the newborn
excluded from the study. In the case of surgery and/or
anesthesia, the propranolol eye micro-drops treatment was to be
discontinued for at least 24 h. Then, the study was to recommence
by reducing the dosage to two micro-drops four times daily
in each eye. Similarly, the study was to recommence with an
increase in the concentration of propranolol up to 0.3% in the
case of treatment failure in terms of efficacy during the first stage
of the study, but only if plasma propranolol concentrations were
below the cut off of 20 ng/ml (17).
Ethical Approval and Informed Consent
The study was conducted in accordance with the
recommendations of Good Clinical Practice. The study was
approved by the Italian Medicines Agency Institutional Review
Board and the Ethics Committees of all the participating centers.
Written informed consent was obtained from the parents of the
newborns in accordance with the Declaration of Helsinki.
Statistical Analysis
This study was planned according to the Simon optimal two-
stage design for phase II clinical trials (24). The historical
progression rate from stage 1 ROP to stage 2 plus or 3 plus in
the NICUs involved in the trial was 23.7%, but we maintained
the estimate of 19% that was obtained in a first analysis and had
been used to get authorization from the ItalianMedicines Agency
(17). The treatment was considered effective if it halved this
progression ratio. Hence, considering an alpha error of 0.05 and
a power of 80%, the study analysis plan required 37 participants
to be enrolled in Stage 1, with <6 participants meeting failure
criteria in Stage 1 before Stage 2 was conducted. If Stage 1
criteria was not met, the study would be terminated for lack
of efficacy. If <6 participants met Stage 1 failure criteria, 59
additional participants would be enrolled in Stage 2. A total
of <13 failures of the 96 total participants (in both Stages)
would indicate sufficient promise to warrant further investigation
(Figure 1). Moreover, the study was to be considered a failure if
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the mean propranolol plasma concentration at the steady-state
was >20 ng/mL.
Categorical variables were expressed as counts or percentages
and compared using the chi-square test. Continuous variables
were expressed as mean (SD) if they followed a normal
distribution and if they were compared using an unpaired, two-
sided t-test. If not normally distributed, continuous variables
were expressed as median values (range) and compared using
the Mann-Whitney U-test. The Kolmogorov-Smirnov test was
used to test for normal distribution of continuous data. The null
hypothesis was accepted with a P > 0.05. The efficacy of the
treatment was evaluated by means of the risk ratio (RR), the
ratio between the proportion of subjects progressing to more
advanced-stage ROP in the propranolol group vs. the historical
control group. In the case of a statistically significant reduction
in the RR, the number of needed to treat (NNT) was calculated.
RESULTS
Historical Control Group
In the period 2011–2015, 2,746 very low birth weight (VLBW)
newborns were admitted to the seven NICUs participating in the
trial. The number of newborns with stage 1 ROP at first diagnosis
was 333 (12.1%), and the number of infants with stage 2 plus
or 3 plus was 79 (23.7% of newborns with stage 1 ROP at first
diagnosis and 2.9% of all VLBW newborns). These newborns
represent the historical control group.
Treated Group
Overall, among the 1,131 VLBW newborns admitted, 105 were
eligible for the study. However, 7 newborns were excluded:
5 newborns because they had developed AP-ROP, 1 newborn
for protocol deviation, and 1 newborn because their parents
withdrew their consent to proceed with the treatment after 4
days after enrolment. No newborn was either excluded from
the study nor removed during the study for cardiac reasons.
Electrocardiographic evaluation showed a right bundle branch
block in two infants at enrolment. Cardiac ultrasounds revealed a
ventricular septal defect that was hemodynamically not relevant
in two patients, and a moderate left ventricular hypertrophy in
one infant at the enrolment stage.
A total of ninety-eight newborns were enrolled and received
propranolol 0.2% eye micro-drops (treated group). Treatment
was started at a median of 54.5 (range 20–94) days of life
(at a mean post-menstrual age of 34.2 ± 2.3 weeks), as soon
as stage 1 ROP was diagnosed. Enrolment was performed ∼2
weeks after the first eye examination, which occurred at a mean
post-menstrual age of 31.6 ± 1.1 weeks. The demographic and
perinatal characteristics of the study population are summarized
in Table 1 and compared with the historical control group. Apgar
scores were slightly but significantly higher in the treated group.
A significantly reduced administration of surfactant, but a more
prolonged oxygen supply (mean 67 ± 60 days vs. 53 ± 48 days,
p= 0.037) were both observed in the treated group (Table 1).
The median duration of treatment was 70 (range 12–90)
days. No protracted interruption of treatment was reported,
except for brief suspensions for surgical procedures. Three of
the ninety-eight newborns had been treated with 2 mg/kg/day
TABLE 1 | Demographic, perinatal characteristics, co-morbidities, and
co-interventions of treated and historical cohorts.
Demographic and perinatal
characteristics
Treated
group
Historical
control group
p
Newborns, n 98 333
Gestational age, weeks, mean ± SD 26.7 ± 2.0 26.4 ± 2.1 0.198
Birth weight, g, mean ± SD 877 ± 250 843 ± 234 0.240
Male, n (%) 48 (49) 180 (52.9) 0.501
Cesarean delivery, n (%) 72 (73.5) 254 (76.3) 0.570
Stained amniotic fluid, n (%) 7 (7.14) 16 (4.8) 0.366
Apgar Score, 1min, median (range) 5 (1–9) 5 (0–9) 0.014
Apgar Score, 5min, median (range) 8 (4–10) 8 (0–10) 0.013
Post menstrual age at enrolment, weeks,
mean ± SD
34.2 ± 2.3 34.1 ± 2.8 0.467
CO-MORBIDITIES AND CO-INTERVENTION
Respiratory distress syndrome, n (%) 93 (94.9) 324 (97.3) 0.240
Surfactant treatment, n (%) 78 (79.6) 292 (87.7) 0.043
Duration of oxygen exposure (days),
median (range)
58 (0–458) 44.0 (0–291) 0.047
Bronchopulmonary dysplasiaa, n (%) 64 (65.3) 202 (60.7) 0.407
Candida sepsis, n (%) 5 (5.1) 12 (3.6) 0.504
Other sepsis, n (%) 50 (51) 174 (52.2) 0.831
Number of red blood cell transfusions,
median (range)
5 (0–21) 5 (0–21) 0.333
Intraventricular hemorrhage, grade
3–4, n (%)
18 (18.4) 48 (14.4) 0.341
Post-hemorrhagic hydrocephalus, n (%) 7 (7.1) 17 (5.1) 0.441
Cholestasis, n (%) 26 (26.5) 61 (18.3) 0.075
Necrotizing enterocolitis, n (%) 9 (9.2) 34 (10.2) 0.766
Gastrointestinal perforation, n (%) 8 (8.2) 31 (9.3) 0.729
Surgical closure of patent ductus
arteriosus, n (%)
18 (18.4) 55 (16.5) 0.668
Survival, n (%) 95 (96.9) 329 (98.8) 0.201
a Oxygen requirement at 36 weeks’ postmenstrual age.
of oral propranolol before ROP development (two for cardiac
hypertrophy and one for supra-ventricular tachycardia) and were
then enrolled at the development of ROP stage 1.
Safety
During the study, none of the severe adverse events that are
usually related to propranolol (i.e., bradycardia, bronchospasm,
severe hypotension) or severe local signs were observed. One
newborn showed retinal hemorrhage in the right eye after
40 days of treatment, which appeared the day after mask
ventilation for apnea. Treatment was not discontinued because
a correlation with propranolol was considered unlikely. The
following month, a bilateral retinal pallor was noticed. Treatment
was discontinued after 90 days, and ROP regressed. Forty days
after propranolol eye drops discontinuation, a bilateral cataract
was observed.
Three infants died from causes unrelated to propranolol
eye drops administration. One infant, suffering from chronic
myelomonocytic leukemia, died from multi-organ failure
concomitant with sepsis by Klebsiella Pneumoniae 52 days after
the discontinuation of propranolol treatment. A second infant
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FIGURE 2 | Hemodynamic and respiratory parameters, weight gain and diuresis during the first 21 days of the study.
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TABLE 2 | Biochemical parameters during the study of treated group.
Enrolment 7 days P 14 days P 21 days P
pH 7.36 ± 0.05 7.36 ± 0.06 0.746 7.36 ± 0.06 0.854 7.37 ± 0.05 0.099
pCO2, mmHg, mean ± SD 45.5 ± 8.2 48.2 ± 10.2 0.053 46.8 ± 9.0 0.341 46.9 ± 9.4 0.321
pO2, mmHg, mean ± SD 48.5 ± 18.5 49.1 ± 18.7 0.840 48.7 ± 20.1 0.937 47.8 ± 19.5 0.812
Base Excess, mmol/L, mean ± SD 0.3 ± 4.1 0.6 ± 4.2 0.585 0.6 ± 3.7 0.650 1.2 ± 4.1 0.153
HCO−3 , mmol/L, mean ± SD 25.3 ± 3.9 26.2 ± 4.3 0.107 26.0 ± 3.8 0.211 26.5 ± 4.3 0.040
White blood cells, × 109/L, mean ± SD 11081 ± 5651 11170 ± 5480 0.963 10614 ± 6367 0.518 10386 ± 5107 0.339
Hemoglobin, g/dL, mean ± SD 10.3 ± 1.9 10.5 ± 1.8 0.619 10.4 ± 1.6 0.762 9.9 ± 1.7 0.088
Hematocrit, %, mean ± SD 30.1 ± 5.4 31.1 ± 5.4 0.270 30.8 ± 4.7 0.368 29.4 ± 4.0 0.306
Platelets, ×109/L, mean ± SD 329 ± 139 340 ± 138 0.603 343 ± 129 0.506 347 ± 143 0.425
Glucose, mg/dL, mean ± SD 84 ± 22 81 ± 18 0.372 84 ± 19 0.968 83 ± 18 0.792
Sodium, mEq/L, mean ± SD 138 ± 3.2 138 ± 3.3 0.928 139 ± 3.7 0.124 139 ± 3.1 0.219
Potassium, mEq/L, mean ± SD 4.4 ± 0.7 4.5 ± 0.8 0.296 4.6 ± 0.8 0.069 4.8 ± 0.9 0.002
Chloride, mEq/L, mean ± SD 103 ± 5.4 102 ± 5.5 0.439 103 ± 5.5 0.648 103 ± 5.0 0.502
Total protein, g/L, mean ± SD 4.6 ± 0.6 4.7 ± 0.5 0.946 4.6 ± 0.5 0.701 4.7 ± 0.4 0.878
Urea nitrogen, mg/dL, mean ± SD 20 ± 15 21 ± 19 0.635 21 ± 26 0.690 22 ± 19 0.529
Creatinine, mg/dL, mean ± SD 0.39 ± 0.3 0.39 ± 0.4 0.848 0.36 ± 0.3 0.464 0.30 ± 0.1 0.008
Aspartate transaminase, U/L, mean ± SD 46 ± 42 48 ± 39 0.770 50 ± 56 0.848 38 ± 22 0.121
Alanine transaminase, U/L, mean ± SD 31 ± 33 30 ± 29 0.906 31 ± 36 0.935 26 ± 23 0.326
Total bilirubin, mg/dL, mean ± SD 2.2 ± 3.0 1.8 ± 2.3 0.311 1.4 ± 2.1 0.057 1.1 ± 1.2 0.004
Conjugate bilirubin, mg/dL, mean ± SD 1.6 ± 2.8 1.3 ± 2.1 0.555 1.2 ± 2.1 0.458 0.6 ± 0.8 0.018
C-reactive protein, mg/dL, mean ± SD 0.69 ± 1.6 0.60 ± 1.2 0.694 0.87 ± 2.6 0.605 0.61 ± 1.7 0.784
T-test was evaluated between values at enrolment and values after 7, 14, or 21 days of treatment.
FIGURE 3 | Plasma propranolol concentrations measured by dried blood spots in the newborns treated with 0.2% eye micro-drops (continuous black line), in the tenth
day of treatment, compared with plasma concentrations obtained in the previous studies after 0.1% eye micro-drops (continuous gray line) (15), oral 1 mg/kg/day
(dotted gray line) or oral 2 mg/kg/day (dotted gray line) propranolol administration (A) (9). Magnification of results observed with 0.2 and 0.1% eye micro-drops (B).
died from suspected viral sepsis 69 days after the discontinuation
of propranolol treatment. A third infant, suffering from multiple
thromboembolism, died because of renal failure after 24 days
of treatment, with ROP stable at stage 2, but before ROP had
completed its evolution, and therefore he was excluded from the
outcome analysis.
Hemodynamic and respiratory parameters, weight gain and
diuresis, continuously monitored during the first 21 days of
treatment, did not present relevant abnormalities (Figure 2), and
were in line with values observed after the administration of 0.1%
propranolol eye micro-drops (16). Regarding the biochemical
parameters that were monitored during the study, no substantial
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differences were observed between the values at the enrolment
stage and the values after 7, 14, or 21 days. The decrease of
total and conjugate bilirubin was compatible with a progressive
improvement of the liver function. The only effect probably
related to propranolol was the moderate increase of potassium
values (also observed in a previous study) (10), although all values
were within the normal range (Table 2).
Newborns who were clinically stable after the first 3 weeks of
treatment, were discharged and continued treatment at home. No
extended hospital stays were observed for newborns involved in
the study.
Plasma Propranolol Level
Propranolol dried blood spots were obtained from 91 of
the 98 patients. Large inter-individual differences in plasma
concentrations were observed between the patients, and 20
infants showed plasma propranolol values steadily <2.5 ng/mL.
The CV of propranolol values was very high (0.77 at T0, 0.82 at
T2, 0.88 at T4, and 0.77 at T6). The mean plasma propranolol
level on the 10th day (steady-state) was consistently below the
cut-off value of 20 ng/mL (Figure 3). These values were ∼50–
80% higher than the values obtained with eye drops at 0.1%
(16), and approximately 5 times lower than that reported after
oral administration of 1 mg/kg/day of propranolol (10). Only
one infant showed propranolol values higher than 20 ng/mL
(27 ng/mL) after 2 h of eye micro-drops administration.
Efficacy
After the enrolment of the first 37 infants, only 2 patients
progressed to ROP stage 2 or 3 plus, and the mean plasma
propranolol level was around 3–4.2 ng/mL. Therefore, the study
progressed to the second stage, and all the planned newborns
were enrolled. The analysis of the ophthalmologic outcome was
performed for the 97/98 newborns that completed treatment.
Overall, 12/97 newborns (12.4%) progressed to stage 2 plus
or 3 plus (six to stage 2 plus and six to stage 3 plus),
approximately half of what had been observed in historical
control group (RR 0.521, 95% CI 0.297-0.916; p = 0.0235) and,
therefore, the study suggested a possible efficacy of this treatment
(Figure 4). The number of NNT to prevent one additional bad
outcome was 8.8 (95% CI 4.8-45.9). In addition, newborns
treated with propranolol showed a trend toward a reduced
progression to stage 2 (RR 0.855, 95% CI 0.715-1.021; p= 0.083)
and to stage 3 without plus (RR 0.724, 95% CI 0.491-1.069;
p = 0.104). Consequently, the number of treatments with laser
or bevacizumab was significantly reduced by propranolol eye
micro-drops (RR 0.468, 95% CI 0.242-0.905; p = 0.024 and RR
0.381, 95% CI 0.118-1.230; p= 0.107, respectively). Nine of them
received laser therapy and three received anti-VEGF injections.
No newborns progressed to stage 4 or 5, and no newborn
was treated with vitrectomy or cryotherapy, but the number of
patients in these stages was also too small in the historical group
to obtain statistically meaningful results (Table 3).
The six newborns who progressed to stage 2 plus were treated
with laser or anti-VEGF earlier than those six that progressed to
stage 3 plus (21 ± 9 vs. 27 ± 8 days; p = 0.291). The mean age
and the birthweight of newborns who needed laser or anti-VEGF
treatment were significantly lower when compared with the
overall population of the study (25.3 ± 1.2 vs. 26.7 ± 2.0 weeks,
p = 0.0019; 702 ± 142 vs. 877 ± 250 g, p = 0.0192), confirming
the importance of these two risk factors. Failed newborns also
showed a higher incidence of co-morbidities (increased incidence
of intestinal perforation, sepsis, intra-ventricular hemorrhage),
but statistical significance was observed exclusively for a higher
incidence of surgical patent ductus arteriosus (58.3% vs. 18.4%,
p= 0.0017).
Finally, 37 newborns continued propranolol treatment for 90
days because the retinal vascularization had not completed, but
no rebound was reported when treatment was discontinued.
Unexpectedly, all three patients treated for cardiac diseases
with oral propranolol before the appearance of ROP who then
enrolled after ROP stage 1 development, were then unresponsive
to propranolol eye micro-drops and needed laser or anti-
VEGF treatment.
DISCUSSION
This trial, using the Simon two-stage optimal design, showed
that propranolol 0.2% eye micro-drops are safe and probably
effective in reducing the expected progression of ROP from
stage 1 to stage 2 plus or 3 plus. In our historical group,
this progression occurred in 23.7% of the infants, a value
in line with incidence reported in the ETROP Cooperative
Group study (25) and additional studies (26), corresponding
to the 2.9% of all VLBW admitted, and in line with incidence
recently reported in UK (27), while topic ocular propranolol
reduced this progression rate to 12.4% (corresponding to the
1.1% of all VLBW admitted). The mean plasma propranolol
levels were consistently below the cut-off value of 20 ng/mL, and
the biochemical, hematologic, hemodynamic, and respiratory
parameters in the treated newborns were reassuring. No adverse
effects and no increase in hospitalization were observed after
topical administration of propranolol 0.2%. Micro-drops were
also well-tolerated locally, without any signs of topical injury,
despite the treatment being started earlier and at double the
concentration of the one used in our previous study (16). No
rebound was reported, probably because 90 days as an extreme
term of treatment was an acceptable limit.
Comparing the results of this trial with the previous one (16),
we can conclude that by increasing the dose from 0.1 to 0.2%, we
reduced the progression of ROP by 50%, without adverse effects
and with low plasma concentration. However, the optimal dosage
and concentration of the propranolol eye micro-drops are still
uncertain. Nevertheless, we cannot exclude that an even higher
dose might further increase the efficacy of treatment, without
compromising safety and tolerability.
One of the most unexpected results of this study was the
observation that all 3 newborns treated with oral propranolol
before the development of ROP for heart conditions, failed to
respond to eye micro-drops treatment. A fourth newborn, who
had been treated with oral propranolol in the first weeks of life,
before ROP appearance, but had not been enrolled in the trial
because a stage 2 ROP was detected in the first examination,
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FIGURE 4 | Schematic representation of the results of the trial.
TABLE 3 | Ophthalmologic outcome.
ROP progression Treated
group
Historical control
group
p Risk ratio
(95% CI)
Newborns, n 97 333
Stage 2, n (%) 58 (59.8) 233 (70) 0.083 0.855 (0.715–1.021)
Stage 3, n (%) 23 (23.7) 109 (32.7) 0.104 0.724 (0.491–1.069)
Stage 2 or 3 ROP with plus, n (%) 12 (12.4) 79 (23.7) 0.023 0.521 (0.297–0.916)
Stage 4 ROP, n (%) 0 4 (1.2) 0.513 0.379 (0.021–6.973)
Stage 5 ROP, n (%) 0 1 (0.3) 0.938 1.136 (0.047–27.669)
Treatment with laser photocoagulation, n (%) 9 (9.3) 66 (19.8) 0.024 0.468 (0.242–0.905)
Treatment with bevacizumab, n (%) 3 (3.1) 27 (8.1) 0.107 0.381 (0.118–1.230)
Vitrectomy, n (%) 0 4 (1.2) 0.513 0.379 (0.021–6.973)
Cryotherapy, n (%) 0 1 (0.3) 0.938 1.136 (0.047–27.669)
developed a dramatically aggressive ROP (bilateral stage 4)
despite laser treatment and vitrectomy. In the study protocol, no
exclusions had been foreseen for newborns receiving propranolol
prior to the occurrence of ROP. Therefore, the enrolment of
these newborns was inevitable. However, this finding deserves
some speculation.
This probable protective effect of propranolol during the
proliferative phase together with a probable deleterious effect
during the ischemic phase are compatible with the bi-phasic and
“specular” pathogenesis of ROP and the role of the β-adrenergic
system in the different stages of the disease. It is plausible, in fact,
that the administration of propranolol, a molecule able to reduce
the production of VEGF, may be effective during the proliferative
phase of ROP, when VEGF is dramatically increased and a
reduction of VEGF is required, but detrimental if administered
during the ischemic phase, when levels of VEGF are too low to
permit a normal vascularization of the retina and an increase of
VEGF is suitable. This apparent contradictory effect has in fact
already been described for other molecules, such as VEGF or NO,
which may be useful if administered during the ischemic phase,
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but harmful during the proliferative phase (28–31). Based on our
results, we speculate that propranolol is only useful during the
proliferative phase of ROP, while we cannot exclude that during
the ischemic phase the agonism of β-AR might prevent or reduce
the retinal vaso-obliteration, thanks to the ability of the β-AR
associated increase of VEGF. In fact, β-AR agonists have been
shown to ameliorate the retinal damage in experimental models
of diabetic retinopathy, preventing the degeneration of retinal
capillaries (32, 33). Nevertheless, in contrast with our data on
the possible detrimental effects of early exposure to propranolol
on ROP development, Sanghvi et al. recently investigated, in
a randomized controlled trial, the early use of low-dose oral
propranolol for the prevention of ROP. Propranolol started on
the 7th day of life and maintained up to a corrected GA of 37
weeks or complete retinal vascularization did not aggravate ROP
and they even observed a non-statistically significant trend in
ROP reduction (34). Altogether, the current data warrants further
pre-clinical investigations to confirm our results suggesting a
protective role of β-ARs during the ischemic phase of ROP. Our
hypothesis that oxygen-induced vaso-obliteration in response to
hyperoxia occurs through β-ARs down-regulation, which could
in turn be exacerbated by the blockade of β-ARs, needs to be
further explored in animal models.
Regarding the optimal time to start the eye drop treatment,
it is likely that the early start of propranolol administration at
stage 1 ROP may have contributed to the greater effectiveness
if compared to the previous 0.1% trial (16). However, the
negative outcome in newborns treated with propranolol during
the “ischemic phase” of ROP suggests that propranolol cannot be
considered as a preventive treatment for ROP, but rather a risk
factor for a more aggressive ROP. Therefore, the only possible
strategy to increase the efficacy of propranolol topical treatment
might be to increase the dose and not to start the treatment before
ROP appearance.
Although this study suggests that topical administration of
propranolol 0.2% eye micro-drops is an effective therapeutic
approach to counteracting ROP progression, some limitations
have to be discussed.
Limitations
The design of the trial, based on a comparison with a historical
group and without a prospective control group, implies that
this study basically has an exploratory purpose, and does not
allow for definitive conclusions to be drawn. For example, the
perinatal characteristics and the clinical management of the
two compared populations were not perfectly homogeneous (as
demonstrated by the differences in the Apgar score and the
different incidence rate in surfactant administration and oxygen
exposure). We cannot exclude that these differences may have
impacted ROP occurrence and progression, although it is difficult
to assess in which direction. Moreover, we cannot exclude that
laser or anti-VEGF treatments have always been appropriate,
considering that sometimes a number of infants were treated
with a clinical diagnosis milder than stage 2 or 3 plus ROP
(35). Therefore, only a prospective placebo-controlled study can
avoid bias arising, respectively, from non-homogeneous groups
or uneven intervention criterion for laser photocoagulation or
anti-VEGF treatment.
We observed a high variability in plasma propranolol
concentration. The considerable inter-subject variability
had been previously observed, probably because of the
variability in absorption and metabolism (23). However, in
this study, many other biases could have influenced this
variability. The compression of the lacrimal sac following
the application of each micro-drop can have variable efficacy
between patients. Moreover, adherence or non-adherence to
the correct compression of the lacrimal ducts has not been
thoroughly evaluated in this study, and this point should be
well-analyzed in future studies. Moreover, the delivery system is
a pipette that is not specifically designed for the current purpose
and nurses/parents have learned to use it in a short time. So, we
cannot exclude that the high variability might also be due to the
inaccurate administration of the eye micro-drops. Interestingly,
3 of the 12 failed patients showed plasma propranolol values
under the detection limit of the analytical system (<2.5 ng/mL)
(22). Therefore, it is likely that a more reliable delivery system
could guarantee a more constant concentration of the drug and
probably better results.
Propranolol is a non-selective β-AR antagonist,
predominantly active on β1 and β2-ARs. Recent findings
demonstrated that β3-ARs are also actively involved in hypoxia-
induced retinal neo-vascularisation (36, 37). It is possible that
in the near future, the antagonism of β-ARs might also include
β3-AR blockers, but unfortunately, currently there are no
approved blockers for targeting this receptor in humans.
CONCLUSION
In conclusion, this second phase IIB study shows that
propranolol 0.2% eye micro-drops reduced ROP progression
when administered during the proliferative phase of the disease.
Propranolol treatment was well-tolerated even in preterm
newborns with a high prevalence of co-morbidities. Therefore,
subsequent confirmations from randomized placebo-controlled
trials are definitely warranted.
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